Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST
On May 5, 2022, Processa Pharmaceuticals (NASDAQ: PCSA) announced a conference call scheduled for May 12, 2022, at 4:30 p.m. EST to review Q1 results and update its clinical pipeline. Interested participants can join via phone or a live webcast. The company focuses on developing treatments for unmet medical needs, with active programs in metastatic colorectal cancer, breast cancer, and gastroparesis. The call will provide insights into the company's progress and future goals.
- None.
- None.
HANOVER, MD, May 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a conference call and live webcast on May 12, 2022 at 4:30 p.m. EST to discuss its results for the first quarter and provide an update on its clinical pipeline.
Conference Call Information
To participate in this event, please log-on or dial-in approximately 5 to 10 minutes before the beginning of the call.
Date: May 12, 2022
Time: 4:30 p.m. ET
Toll Free: 877-545-0320
International: 973-528-0002
Entry Code: 896576
Live Webcast: https://www.webcaster4.com/Webcast/Page/2572/45432
Conference Call Replay Information
Toll-free: 877-481-4010
International: 919-882-2331
Replay Passcode: 45432
Replay Webcast: https://www.webcaster4.com/Webcast/Page/2572/45432
About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent reports on Forms 10-K and 10-Q, which identify important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
For More Information:
Michael Floyd
mfloyd@processapharma.com
301-651-4256
Patrick Lin
925-683-3218
plin@processapharma.com
FAQ
When is the Processa Pharmaceuticals conference call to discuss Q1 results?
How can I participate in the Processa Pharmaceuticals conference call?
What is the purpose of the Processa Pharmaceuticals conference call on May 12, 2022?
What are some of the active clinical programs of Processa Pharmaceuticals?
What is the entry code for the Processa Pharmaceuticals conference call?
